The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Boehringer Ingelheim is playing catch-up with Novo Nordisk and Lilly in obesity, but is hoping a higher dose and a more patient-friendly titration can help it prove that survodutide is a contender.

Chinese firm Hasten has gained greater China rights to LIB Therapeutics’ lerodalcibep for hypercholesterolemia and believes its bet on the unique PCSK9-binding small protein will be backed by strong commercialization capability, the company says in an interview with Scrip.

Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.